Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET
about
Cytoplasmic targeting of the proto-oncogene SET promotes cell spreading and migrationProtein Phosphatase 2A as a Therapeutic Target in Acute Myeloid LeukemiaThe Rac1 hypervariable region in targeting and signaling: a tail of many storiesThe Basic Biology of PP2A in Hematologic Cells and MalignanciesMembrane recruitment of scaffold proteins drives specific signalingRac1 recruits the adapter protein CMS/CD2AP to cell-cell contacts.XIAP BIR domain suppresses miR-200a expression and subsequently promotes EGFR protein translation and anchorage-independent growth of bladder cancer cellSilencing PP2A inhibitor by lenti-shRNA interference ameliorates neuropathologies and memory deficits in tg2576 mice.Toward understanding RhoGTPase specificity: structure, function and local activation.A comprehensive analysis of 3' end sequencing data sets reveals novel polyadenylation signals and the repressive role of heterogeneous ribonucleoprotein C on cleavage and polyadenylationMutations in genes involved in nonsense mediated decay ameliorate the phenotype of sel-12 mutants with amber stop mutations in Caenorhabditis elegansRegulating Set-β's Subcellular Localization Toggles Its Function between Inhibiting and Promoting Axon Growth and Regeneration.Silencing [Formula: see text] Rescues Tau Pathologies and Memory Deficits through Rescuing PP2A and Inhibiting GSK-3β Signaling in Human Tau Transgenic Mice.Nucleophosmin1 is a negative regulator of the small GTPase Rac1.Cytoplasmic retention of protein phosphatase 2A inhibitor 2 (I2PP2A) induces Alzheimer-like abnormal hyperphosphorylation of Tau.Proteogenomic analysis of human chromosome 9-encoded genes from human samples and lung cancer tissues.67-kDa laminin receptor-dependent protein phosphatase 2A (PP2A) activation elicits melanoma-specific antitumor activity overcoming drug resistance.SCF E3 ligase F-box protein complex SCF(FBXL19) regulates cell migration by mediating Rac1 ubiquitination and degradationMYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductaseThe beta-arrestin pathway-selective type 1A angiotensin receptor (AT1A) agonist [Sar1,Ile4,Ile8]angiotensin II regulates a robust G protein-independent signaling network.Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapyThe N-terminal Set-β Protein Isoform Induces Neuronal DeathOverexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer.Evaluation of 9-cis retinoic acid and mitotane as antitumoral agents in an adrenocortical xenograft model.SET protein interacts with intracellular domains of the gonadotropin-releasing hormone receptor and differentially regulates receptor signaling to cAMP and calcium in gonadotrope cells.Alternative polyadenylation can regulate post-translational membrane localization.Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease.MiR-502-3P suppresses cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting SET.Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signalingAntagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignanciesStable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models.Evolution and Biological Roles of Alternative 3'UTRs.Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer.SET/I2PP2A overexpression induces phenotypic, molecular, and metabolic alterations in an oral keratinocyte cell line.Spatial perspectives in the redox code-Mass spectrometric proteomics studies of moonlighting proteins.Alternative 3' UTRs act as scaffolds to regulate membrane protein localizationDivergent behaviors and underlying mechanisms of cell migration and invasion in non-metastatic T24 and its metastatic derivative T24T bladder cancer cell linesTargeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.SET overexpression decreases cell detoxification efficiency: ALDH2 and GSTP1 are downregulated, DDR is impaired and DNA damage accumulates.
P2860
Q24305121-C983FB50-49E2-4B13-B133-48273277BAF0Q26752430-8E21BE47-ADA2-4ABE-9CC9-44BED1A996B3Q26864271-C5092567-C9FF-420B-9C7C-45FB678EE127Q28088697-3990E7AC-0842-457E-8837-FEFB29F9AB90Q28469311-3C60335F-CA60-4528-802D-34111684EF6BQ30156899-5BE214F5-041E-463F-A5EA-C0C2E2F61086Q30354484-F70388C6-E294-41B9-8831-76B879D8FC8EQ30559506-4DC5D141-1D89-409C-86D5-1386C428ECA6Q30667628-E611018D-575F-4209-9DC6-A82389B7C1D6Q31112743-15FDCBE9-8649-49A6-B5F8-65661DB12894Q33420094-576339FE-61F6-4B81-A513-D67D5E6E90C2Q33639540-E036C7F5-36D7-4ECC-BDA2-64405D60C7B1Q33766526-2802ABAD-0489-415F-9822-927DADB9C1B9Q34037545-3710D874-8CE0-42A3-821A-A3FC9A8BB2FBQ34283467-6F96AB70-4F48-410C-A577-81430CEBAD2AQ34387657-461FC96A-CA30-4996-8829-1466949CF15FQ34552639-4CD0431C-904E-4886-AE3A-676DD888E93BQ34628087-C4C44CCA-6B4A-4038-BEC1-2C60B5030CEAQ34687185-503683F1-A9FD-43B6-A4F4-463C430375C4Q35011083-50F22FD0-78E5-40DA-BDC4-AF3BDE279CCBQ35022139-9DFB5A23-2070-4B4B-B447-F212B0F3BFDBQ35861000-D022B9EB-55A3-4B25-B07F-FC5109767B52Q35944719-1A221205-D519-4E6E-AEF6-5B9CBDF45325Q36050039-52F12286-7806-4A92-BFCA-C262386C8AECQ36516597-BEF9C5C2-3502-463D-BB47-41A0084B3521Q36562076-1435109E-9DC8-4F77-B82F-51B394BE3F42Q36630940-B458EA18-0B43-41CA-9FD2-51822F94D90AQ36929023-9F6AF884-F14A-4207-AB45-C51DCB758B79Q36982248-F15B3560-E9D6-4A35-BB3A-EFBF5D9EE59EQ37123974-E89638BE-F47D-46B2-A525-DF1C96A1F6D9Q37169105-5C414C46-68F5-48B6-A646-51746A6E0185Q37607196-A222FB51-ED70-411C-98E3-2376AD1A2A66Q38644580-710A9151-88B3-4211-AC5C-EB075FE99397Q38678579-5A23102B-7AF9-48F0-BB29-26EC3B4A7F71Q38699543-4FCAB929-8F81-4AB9-A083-402FF91F46B5Q38836196-81723924-38CC-4CCA-B407-642E075A4CD7Q38884226-C92FD501-A96A-4EF1-9AF9-AFDA4340C72BQ38939993-FB60B2FF-3399-4197-A998-943498698965Q39097201-E0A4D07C-452E-4A47-9543-A1F9C60C8E0CQ39252301-4AF53561-C15F-4395-B0D5-9CDA5FDEBF2A
P2860
Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET
@ast
Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET
@en
Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET
@en-gb
Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET
@nl
type
label
Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET
@ast
Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET
@en
Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET
@en-gb
Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET
@nl
prefLabel
Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET
@ast
Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET
@en
Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET
@en-gb
Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET
@nl
P2093
P2860
P3181
P356
P1433
P1476
Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET
@en
P2093
Eloise C Anthony
Ingrid v Leeuwen
Jean Paul ten Klooster
Nina Scheres
Peter L Hordijk
P2860
P304
P3181
P356
10.1038/SJ.EMBOJ.7601518
P407
P577
2007-01-24T00:00:00Z